

new interesting radioimmunotherapy and other radioactive compounds under clinical development. For successful integration of these compounds into the clinical arena, we need to focus not only on scientific evidence but also on logistic and economic issues.

DISCLOSURE STATEMENT

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

ACKNOWLEDGMENTS

Dr. Richard L. Wahl is one of the inventors of anti-CD20 radioimmunotherapy and receives payments from the University of Michigan as part of a patent licensing agreement related to royalties from the U.S. sales of the radioimmunotherapy agents ¹³¹I-tositumomab and ⁹⁰Y-ibritumomab tiuxetan. This arrangement has been disclosed to and is managed by the JHU COI Committee.

REFERENCES

1. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. *N Engl J Med.* 2008;359:613–626.
2. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [¹³¹I]anti-B1 (anti-CD20) antibody. *N Engl J Med.* 1993;329:459–465.
3. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. *J Clin Oncol.* 2000;18:1316–1323.
4. Kaminski MS, Tuck M, Estes J, et al. ¹³¹I-tositumomab therapy as initial treatment for follicular lymphoma. *N Engl J Med.* 2005;352:441–449.
5. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. *J Clin Oncol.* 2002;20:2453–2463.
6. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. *Blood.* 2002;99:4336–4342.
7. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. *J Clin Oncol.* 2002;20:3262–3269.
8. Link BK, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. *J Clin Oncol.* 2010;28:3035–3041.
9. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. *J Clin Oncol.* 2008;26:5156–5164.
10. Berenson A. Market forces cited in lymphoma drugs' disuse. *The New York Times.* July 14, 2007. Available at: <http://www.nytimes.com/2007/07/14/health/14lymphoma.html>. Accessed March 11, 2011.
11. Illidge TM. Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date? *J Clin Oncol.* 2010;28:2944–2946.
12. Schaefer NG, Ma J, Huang P, Buchanan J, Wahl RL. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists. *J Nucl Med.* 2010;51:987–994.
13. National Comprehensive Cancer Network (NCCN). *Non-Hodgkin's Lymphomas. NCCN Clinical Practice Guidelines in Oncology, v.1.2010.* Fort Washington, PA: NCCN; 2010.
14. Hewson C, Yule P, Laurent D, Vogel C. *Internet Research Methods: A Practical Guide for the Social and Behavioural Sciences.* London, U.K.: Sage Publications Ltd.; 2003.
15. Salles GA, Seymour JF, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy [abstract]. *J Clin Oncol.* 2010;28(suppl):15s.
16. Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. *Cancer.* 2005;103:1644–1651.
17. Centers for Medicare and Medicaid Services, Department of Health and Human Services. CMS Programs & Information: Medicare. Available at: <http://www.cms.hhs.gov/>. Accessed March 11, 2011.

Erratum

In the article “Searching for Alternatives to Full Kinetic Analysis in ¹⁸F-FDG PET: An Extension of the Simplified Kinetic Analysis Method,” by Hapdey et al. (*J Nucl Med.* 2011;52:634–641), the name of the third author was misspelled. The correct spelling is Joann M. Carson. The authors regret the error.